GlassScriptPhysician profile
Charles Gia Phan
NPI 1457303737
$138,806.55
in general payments reported to CMS, 2019-2025
21 companies · $9,246 in 2025
The $9,246 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $6,873 · 2021: $16K · 2022: $38K · 2023: $13K · 2024: $11K · 2025: $9,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $3,807 · Food and Beverage: $1,860 · Consulting Fee: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,570.00 |
| Travel and Lodging | $3,806.86 |
| Food and Beverage | $1,860.19 |
| Consulting Fee | $1,630.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $132,616.41 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $2,722.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,310.25 | 2019-2024 | Xifaxan |
| Allergan, INC. | $170.47 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $167.41 | 2021 | |
| Medtronic, INC. | $147.54 | 2022 | |
| Intra-Sana Laboratories | $125.04 | 2021 | |
| Intercept Pharmaceuticals, INC. | $102.76 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $97.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $65.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.62 | 2022-2023 | Gattex |
| Ardelyx, INC. | $45.66 | 2023 | Ibsrela |
| Qol Medical, LLC | $40.08 | 2022 | |
| Shionogi INC | $29.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.79 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $17.11 | 2021 | |
| Orphalan INC | $17.02 | 2025 | Cuvrior |
| Janssen Biotech, INC. | $15.80 | 2023 | Stelara, Simponi Aria, Simponi |
| Exact Sciences Corporation | $15.14 | 2023 | Cologuard Collection Kit |
| Olympus America INC. | $11.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.